Laboratory abnormalities in the primary analysis1

Laboratory Abnormalities That Worsened From Baseline to Grade 3 or 4 Occurring in ≥1% of Patients With dMMR Endometrial Cancer Receiving JEMPERLI in GARNET

Chart displaying laboratory abnormalities that worsened from baseline to Grade 3 or 4 Occurring in >/= 1% of patients with dMMR Endometrial Cancer Receiving JEMPERLI (dostarlimab-gxly) in GARNET

*

Intention-to-treat population (N=104).

Consists of new onset of laboratory abnormality or worsening of baseline laboratory abnormality.

 

Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1–blocking antibodies.1

 

dMMR=mismatch repair deficient; PD-1=programmed death receptor 1; PD-L1=programmed death ligand 1.

Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

Find out how to dose and
administer JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Support

Get support for
JEMPERLI at every step.

Icon: JEMPERLI (dostarlimab-gxly) Trial

Explore the pivotal trial
for JEMPERLI.